Cefepime as Empirical Peritoneal Dialysis–Associated Peritonitis Treatment: Something to Dwell On?

Peritoneal dialysis (PD)-associated peritonitis carries substantial morbidity, contributing to death in up to 8.6% of patients.1 Peritonitis increases treatment costs and hospitalization events and is the leading cause of premature transition to hemodialysis.2 Peritonitis was identified as a core outcome of importance to patients, caregivers, and health professionals in the SONG (Standardised Outcomes in Nephrology) PD initiative.3 Peritonitis rates have improved due to advances in PD connectology and other preventative strategies and have been reported to be as low as 0.08 to 0.26 episode per patient-year among facilities in the United States and Japan.